INT119102

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 11.99
Pain Relevance 0.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (PDGFRA) nucleus (PDGFRA) extracellular matrix organization (PDGFRA)
cytoplasm (PDGFRA)
Anatomy Link Frequency
urinary bladder 2
platelet 2
eosinophils 1
lung 1
stem 1
PDGFRA (Homo sapiens)
Pain Link Frequency Relevance Heat
positron emission tomography 9 92.72 High High
palliative 6 92.48 High High
Dysuria 2 88.92 High High
Piles 2 75.04 Quite High
fibrosis 5 73.44 Quite High
methotrexate 2 67.20 Quite High
abdominal pain 4 61.76 Quite High
cINOD 5 58.56 Quite High
cva 17 57.60 Quite High
Pain 21 33.44 Quite Low
Disease Link Frequency Relevance Heat
Cancer 231 99.98 Very High Very High Very High
Cervical Cancer 8 99.98 Very High Very High Very High
Adenoid Cystic Carcinoma 1 99.80 Very High Very High Very High
Ovarian Cancer 200 99.76 Very High Very High Very High
Small Cell Lung Cancer 10 99.34 Very High Very High Very High
Sarcoma 5 99.18 Very High Very High Very High
Disease 146 99.16 Very High Very High Very High
Malignant Neoplastic Disease 20 99.16 Very High Very High Very High
Seminoma 1 98.88 Very High Very High Very High
Skin Cancer 7 98.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The product of this fusion gene, FIP1L1-PDGFRalpha, is a constitutively active protein-tyrosine kinase capable of transforming hematopoietic cells.
Gene_expression (product) of PDGFRalpha in hematopoietic cells
1) Confidence 0.75 Published 2004 Journal Semin. Oncol. Section Abstract Doc Link 15175999 Disease Relevance 1.01 Pain Relevance 0.11
This effect is presumably due to tumor expression of activated receptor tyrosine kinases c-kit and/or platelet-derived growth factor receptor-alpha (PDGFRA).
Gene_expression (expression) of PDGFRA in platelet associated with cancer
2) Confidence 0.75 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2438440 Disease Relevance 0.73 Pain Relevance 0.09
Although their overall incidence is low, GISTs are distinctive subgroup of gastrointestinal mesenchymal tumors which express CD117 or platelet derived growth factor receptor alpha (PDGFRA).
Gene_expression (express) of PDGFRA in platelet associated with cancer
3) Confidence 0.75 Published 2010 Journal Chirurgia (Bucur) Section Abstract Doc Link 20941986 Disease Relevance 1.31 Pain Relevance 0.09
The present case is the first case of primary small cell carcinoma of the urinary bladder involving examination of KIT and PDGFRA expression and KIT and PDGFRA gene mutations.
Gene_expression (expression) of PDGFRA in urinary bladder associated with small cell lung cancer
4) Confidence 0.68 Published 2009 Journal Pathol. Int. Section Abstract Doc Link 19351368 Disease Relevance 0.59 Pain Relevance 0.06
Autopsy case of primary small cell carcinoma of the urinary bladder: KIT and PDGFRA expression and mutations.
Gene_expression (expression) of PDGFRA in urinary bladder associated with small cell lung cancer
5) Confidence 0.68 Published 2009 Journal Pathol. Int. Section Title Doc Link 19351368 Disease Relevance 0.60 Pain Relevance 0.09
The following terms are currently used in medical literature to qualify different patient subsets among those fulfilling the diagnostic criteria of HES:

• FIP1L1-PDGFRA(F/P)-associated HES, or F/P+ HES, for patients with clonal hypereosinophilia due to a sporadic hematopoiëtic stem cell chromosomal rearrangement resulting in fusion of two genes (FIP1L1 and PDGFRA) on 4q12; these patients are more appropriately classified as F/P+ chronic eosinophilic leukemia. • Chronic eosinophilic leukemia (CEL), for patients in whom clonality of eosinophils has been demonstrated (including those with the FIP1L1-PDGFRA fusion), or who present increased blasts; occasional reports indicate that some patients with CEL progress towards acute myeloid or eosinophilic leukemia. • Lymphocytic-HES (L-HES), for patients with chronic reactive (polyclonal) hypereosinophilia secondary to IL-5 over-production by T cells. • Myeloproliferative-HES (M-HES) may be used for patients with an array of clinical and biological features suggesting the possible existence of an underlying myeloproliferative disorder associated with hypereosinophilia, although underlying molecular defects are not detected (including increased serum vitamin B12, hepato- and/or splenomegaly, anemia and/or thrombocytopenia, circulating myeloid precursors, dysplastic eosinophils, bone marrow hypercellularity with left shift in maturation, myelofibrosis, increased serum tryptase, and response to imatinib); this term is occasionally extended more largely to include patients with known molecular defects (e.g.

Gene_expression (fusion) of PDGFRA in eosinophils associated with myeloproliferative disorder, anaemia, splenomegaly, hypereosinophilic syndrome, thrombocytopenia, myelofibrosis and hyperplasia
6) Confidence 0.50 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2045078 Disease Relevance 1.94 Pain Relevance 0
Several other human cancers, as small-cell lung carcinoma, melanoma, seminoma, some sarcomas, and adenoid cystic carcinomas may over-express KIT or PDGF-R, and clinical trials to evaluate the role of IM in the treatment of such cancers are currently ongoing.
Gene_expression (express) of PDGF-R in lung associated with sarcoma, seminoma, lung cancer, cancer, adenoid cystic carcinoma and skin cancer
7) Confidence 0.50 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 1.65 Pain Relevance 0.08
PDGF is expressed in 73% of ovarian carcinomas, while 36% express PDGF-receptor alpha (PDGFRA).
Gene_expression (express) of PDGFRA associated with ovarian cancer
8) Confidence 0.27 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.63 Pain Relevance 0
In addition, overexpression of PDGFRA is an independent poor prognostic factor in ovarian carcinoma [57].
Gene_expression (overexpression) of PDGFRA associated with ovarian cancer
9) Confidence 0.27 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.68 Pain Relevance 0
Successively, in a molecular/biochemical analyses of the three receptors targeted by IM (PDGFRB, PDGFRA, and KIT) in a series of 31 chordoma patients, it was proven that PDGFRB was highly expressed and phosphorilated whereas PDGFRA and KIT were less expressed but equally activated [14].
Gene_expression (expressed) of PDGFRA associated with chordoma
10) Confidence 0.07 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2828414 Disease Relevance 0.57 Pain Relevance 0
All patients expressed the PDGFRalpha in more than 10% of malignant cells, whereas only 4 coexpressed the PDGFRbeta.
Gene_expression (expressed) of PDGFRalpha associated with malignant neoplastic disease
11) Confidence 0.02 Published 2009 Journal Int. J. Gynecol. Cancer Section Abstract Doc Link 19955950 Disease Relevance 1.02 Pain Relevance 0.17
A secondary end point was to evaluate its safety as second-line treatment of recurrent or metastatic cervical cancer expressing PDGFRalpha.
Gene_expression (expressing) of PDGFRalpha associated with cervical cancer
12) Confidence 0.01 Published 2009 Journal Int. J. Gynecol. Cancer Section Abstract Doc Link 19955950 Disease Relevance 0.68 Pain Relevance 0.12
One multitarget agent in this emerging antineoplastic category includes sunitinib, which acts as an intracellular tyrosine kinase inhibitor (TKI) of multiple factors, including the intracellular domain of VEGF receptor (VEGFR-1, VEGFR-2), PDGF receptor (PDGFR-alpha and PDGF-beta), fetal liver tyrosine kinase receptor 3 (FLT3), and KIT (stem-cell factor receptor).9,10
Gene_expression (receptor) of PDGFR-alpha in stem
13) Confidence 0.01 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886329 Disease Relevance 0.57 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox